Lucid Diagnostics IncNASDAQ:LUCD
- LAST PRICE1.3600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 1.3600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LUCD |
|---|---|---|
| 09:32 ET | 802 | 1.44 |
| 09:39 ET | 5767 | 1.44 |
| 10:19 ET | 1454 | 1.445 |
| 11:22 ET | 100 | 1.385 |
| 11:29 ET | 100 | 1.38 |
| 11:47 ET | 500 | 1.3882 |
| 12:00 ET | 498 | 1.38 |
| 12:16 ET | 794 | 1.38 |
| 12:36 ET | 600 | 1.3665 |
| 12:48 ET | 313 | 1.3879 |
| 12:50 ET | 313 | 1.3879 |
| 12:59 ET | 100 | 1.3899 |
| 01:10 ET | 100 | 1.3789 |
| 01:28 ET | 2567 | 1.3786 |
| 01:32 ET | 450 | 1.37 |
| 01:35 ET | 111 | 1.348 |
| 01:42 ET | 889 | 1.3466 |
| 02:04 ET | 5000 | 1.35 |
| 02:09 ET | 100 | 1.3499 |
| 02:11 ET | 2427 | 1.35 |
| 02:31 ET | 1200 | 1.35 |
| 02:44 ET | 1000 | 1.345 |
| 02:51 ET | 1026 | 1.33 |
| 02:56 ET | 200 | 1.325 |
| 02:58 ET | 3376 | 1.3384 |
| 03:02 ET | 308 | 1.3797 |
| 03:03 ET | 100 | 1.35 |
| 03:07 ET | 3000 | 1.3412 |
| 03:21 ET | 150 | 1.3716 |
| 03:34 ET | 132 | 1.347 |
| 03:59 ET | 1986 | 1.36 |
Sep 26, 2023
DJ Lucid Diagnostics Price Target Maintained With a $4.00/Share by Cantor Fitzgerald, from 11:55AM ET on Tuesday Sep 26, 2023 by Dow Jones
11:55AM ET on Tuesday Sep 26, 2023 by Dow Jones
Sep 21, 2023
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference, from 8:30AM ET on Thursday Sep 21, 2023 by Dow Jones
8:30AM ET on Thursday Sep 21, 2023 by Dow JonesPAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference, from 8:30AM ET on Thursday Sep 21, 2023 by Dow Jones
8:30AM ET on Thursday Sep 21, 2023 by Dow Jones
Sep 7, 2023
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard(R) Esophageal Precancer Detection, from 9:26AM ET on Thursday Sep 07, 2023 by Dow Jones
9:26AM ET on Thursday Sep 07, 2023 by Dow Jones
Sep 6, 2023
Lucid Diagnostics Releases Positive Data -2-, from 9:00AM ET on Wednesday Sep 06, 2023 by Dow Jones
9:00AM ET on Wednesday Sep 06, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lucid Diagnostics Inc | 64.3M | -0.9x | --- |
United Health Products Inc | 60.3M | -34.7x | --- |
Delcath Systems Inc | 61.4M | -1.2x | --- |
InspireMD Inc | 67.8M | -1.7x | --- |
Vivani Medical Inc | 50.8M | -2.5x | --- |
Beyond Air Inc | 79.3M | -1.3x | --- |
Company Information
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. It is also developing EsoCure, which is an esophageal ablation device to treat dysplastic BE before it can progress to EAC.
Contact Information
- Headquarters
- 360 Madison Avenue, 25Th FloorNEW YORK, NY, United States 10017
- Phone
- 212-949-4319
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Lishan Aklog
- Vice Chairman of the Board
- Stanley Lapidus
- Chief Financial Officer, Company Secretary
- Dennis Mcgrath
- Chief Operating Officer, Executive Vice President
- Shaun Oneil
- Independent Director
- Aster Angagaw
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $59.5M |
|---|---|
Revenue (TTM) | $793.0K |
Shares Outstanding | 43.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.46 |
Book Value | $0.57 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 75.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,958.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
